Research and Clinical Trials

T2008-002 A Phase I Trial of NECTAR (Nelabarine, Etoposide and Cyclophoshamide in T-ALL Relapse): A Joint Study of TACL and POETIC
Brief Description  
This Phase I study evaluates the safety and the maximum tolerated dose of a new chemotherapy combination of nelarabine, etoposide and cyclophosphamide. Patients will be in the study for approximately two and a half months and followed for lifetime.
Who may be Eligible  
Children, adolescents and young adults ages 1-21 years with diagnosis of first relapse of T-cell acute lymphoblastic leukemia (T-ALL) and bone marrow (BM) or T-cell lymphoblastic lymphoma (T-LL). Exclusions include: Down syndrome, previous stem cell transplantation, prior seizure disorder requiring anti-convulsant therapy to treat/prevent seizures in the prior two years.
Pediatric Cancer
IRB Number  
Principal Investigator  
Oesterheld, Javier

For More Information, Contact  Beatriz  G, Perez-Li
Phone:  (704) 446-5285  Fax:  (704) 335-1188  
Address:1025 Morehead Medical Drive Suite 600 Charlotte, NC 28204